Gemcitabine + Cisplatin + Durvalumab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extrahepatic Cholangiocarcinoma
Conditions
Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
Trial Timeline
Aug 23, 2024 → Apr 1, 2028
NCT ID
NCT06440993About Gemcitabine + Cisplatin + Durvalumab
Gemcitabine + Cisplatin + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Extrahepatic Cholangiocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06440993. Target conditions include Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA.
What happened to similar drugs?
0 of 1 similar drugs in Extrahepatic Cholangiocarcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06440993 | Phase 2 | Recruiting |
| NCT05655949 | Phase 2 | Recruiting |
Competing Products
4 competing products in Extrahepatic Cholangiocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 40 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 35 |
| aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil | Merck | Phase 2 | 35 |
| Gemcitabine + Cisplatin + Sorafenib | Bayer | Phase 2 | 32 |